Search

Whether you’ve been diagnosed with a rare cancer or one that’s more common, MSK doctors can provide a second opinion.

… Thursday, December 18, 2025 Learning that you have cancer can be an overwhelming experience. As you begin researching what steps to take after receiving a  cancer diagnosis , you’ll probably hear a lot about getting a second opinion. Memorial Sloan Kettering Cancer Center (MSK) provides second opinions

Ya sea que le hayan diagnosticado un tipo de cáncer poco común u otro más común, los médicos de MSK pueden brindarle una segunda opinión.

… Thursday, December 18, 2025 Enterarse de que tiene cáncer puede ser una experiencia abrumadora. Al comenzar a investigar cómo proceder luego de recibir un  diagnóstico de cáncer , probablemente escuche hablar mucho de una segunda opinión. Memorial Sloan Kettering Cancer Center (MSK) da segundas opiniones

Paige Arnold, who will graduate from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) next spring, has been awarded the 2022 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus Louis V. Gerstner, Jr., for whom the school is named.

… Friday, September 9, 2022 Paige Arnold , who will graduate from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) next spring, has been awarded the 2022 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus

A new drug delivery method could improve treatment of a lethal pediatric brain tumor called diffuse intrinsic pontine glioma.

… Friday, March 14, 2025 Brain tumors are one of the most difficult cancers to treat because of the blood-brain barrier, which protects the brain against toxins. That barrier also means treatments such as chemotherapy  can’t be delivered to tumors in high enough concentrations to be effective. As a result

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

… Saturday, June 4, 2011 The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are

Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease, indicating that cancer diagnostics need to go beyond the analysis of DNA mutations.

… Monday, August 27, 2018 Bottom Line: Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers

Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal surgical cytoreduction.

… Friday, November 13, 2020 Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal cytoreduction — according to a retrospective analysis of patients with newly-diagnosed

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.

… Friday, April 1, 2011 Summary Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers. A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, “Where should I be treated?” Patients diagnosed with

Thetis cells, a class of immune cells first described by MSK researchers in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

… Thursday, May 15, 2025 A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of life had reduced risk of developing a peanut allergy compared with children who avoided peanuts. Now, researchers at Memorial Sloan Kettering Cancer Center

Along with their alluring beauty, minerals — like scientific ideas — open a window onto the history of the world, Dr. Massagué says.

… Friday, October 11, 2024 Joan Massagué, PhD , has been featured in the pages of The New Yorker twice. Once for each of his two passions: cancer biology and mineral collecting. In 2017, his  groundbreaking work on metastasis was highlighted by Pulitzer Prize-winning author and physician-scientist  Siddhartha